Navigation Links
Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
Date:5/31/2012

May 31, 2012 (Bronx, NY) The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.

In a study published last September in Nature Medicine, Einstein researchers demonstrated that some animals inoculated with the altered M. smegmatis are able to generate a robust immune response when challenged with M. tuberculosis.

Despite widespread use of the 90-year-old Bacille Calmette-Gurin (BCG) vaccine and the availability of several anti-TB drugs, TB remains a major global health problem. In 2010, 8.8 million people fell ill with TB and 1.4 million died of the disease, according to the World Health Organization. The situation has worsened in recent years with the rise of multi drug-resistant TB (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), which are especially common in Africa and Asia.

"Novel therapies for TB are urgently needed, particularly a new and effective vaccine," said William Jacobs, Jr., Ph.D., professor of microbiology & immunology and of genetics at Einstein and a Howard Hughes Medical Institute investigator, who led the development of the new vaccine approach and is principal investigator of the NIH grant.

Einstein's vaccine approach emerged from basic studies of how TB bacteria outwit the immune system. Dr. Jacobs and his colleagues worked with M. smegmatis, which in high doses is lethal in mice but does not harm humans. The researchers created a version of M. smegmatis lacking a set of genes, known as ESX-3, considered crucial for evading host immunity. When high doses of the altered bacteria were infused into mice, it became clear that bacteria lacking the ESX-3 genes could no longer evade their hosts' immune system: the mice controlled and cleared the infection through a robust T-cell response the same response a successful TB vaccine would elicit.

Unfortunately, Dr. Jacobs found that removing the same set of genes from M. tuberculosis killed the bacterium which meant M. tuberculosis could not be manipulated in this way to make a vaccine. But Dr. Jacobs and his colleagues found a way around this stumbling block. They took the M. smegmatis bacteria lacking ESX-3 and inserted the analogous set of M. tuberculosis ESX-3 genes. These M. smegmatis bacteria were then infused into mice, which once again fought off the infection. And eight weeks later, when the mice were challenged with high doses of M. tuberculosis which kills mice as well as people these "vaccinated" mice lived much longer than control mice: an average survival time of 135 days vs. 54 days.

Of particular note was the markedly reduced level of TB bacteria found in the animals' tissues. "Most notably," said Dr. Jacobs, "those vaccinated animals that survived for more than 200 days had livers that were completely clear of TB bacteria, and nobody has ever seen that before." Only about one in five mice showed this robust response indicating that the vaccine must be improved before it can be considered sufficiently effective.

With funds from the NIH grant, the researchers will try to make the vaccine more effective by further genetically modifying the bacteria that it uses. They will also develop a manufacturing process for making batches of the vaccine for human use and develop assays for identifying the most potent batches.

The grant "Vaccines for Extensively Drug Resistant Tuberculosis" (1R01AI098925-01) was awarded by National Institute of Allergy And Infectious Diseases, a division of the NIH.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. State Sen. Jeff Klein launches Einsteins new lab
2. Einstein researcher helps lead consortium for $10 million X Prize to sequence genomes of 100 centenarians
3. Einstein College of Medicine receives $5.7 million for developmental disabilities research
4. Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa
5. Einstein scientists find crucial molecule involved in spread of breast cancer
6. Einstein secures $11 million to continue research on brain aging and Alzheimers disease
7. Einstein Montefiore lung specialist to receive award for work with 9/11 rescue workers
8. Feinstein scientists identify abnormal disease pathway in dystonia
9. Susan Band Horwitz, Ph.D., of Einstein, receives lifetime achievement award in cancer research
10. Einstein-Montefiore researcher will test nanoparticles against pancreatic cancer
11. ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... 2017 , ... Yesterday, the President of the United States retracted his condemnation ... are not two sides to hatred, bigotry, discrimination, and a white supremacy nationalist agenda. ... stands against all forms of such hatred and discrimination in this country and globally. ...
(Date:8/19/2017)... ... ... It's A Boy! God’s Gift: A Story of Love”: a children’s book that shows ... God’s Gift: A Story of Love” is the creation of published authors, Dale Anthony ... Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect gift for ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... Immediate Release                Contact: Julian Teixeira, August 18, 2017                    202-478-8564 / jteixeira@thenc.org , ... from their Fathers , Contrary to a father’s perception, ...
(Date:8/18/2017)... ... August 18, 2017 , ... August ... “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance of ... individuals with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance Group, a ... charity drive to generate community support for efforts to educate the local population on ... for all types of cancer. , Each day in America, roughly 4,600 new ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... -- MJAC2017 , the premier cannabis event devoted to ... its leading lineup. MJAC2017 is proud ... specializing in the development of pharmaceutical and consumer products, will ... The Green Organic Dutchman are gold sponsors for the event, ... ...
(Date:8/17/2017)... Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy , will ... Cell-Ess® Universal Titer Boost at the 9 th annual ... 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to ... ... Cell-Ess is the ...
(Date:8/15/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), is now dispensing ... residents. Naloxone is available without a prescription ... G-3320 Beecher Road. ... is intended to block or reverse the effects of ... consciousness. The medication is often carried by first responders ...
Breaking Medicine Technology: